

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM633786

| | | | |
|---|-------------------------------------|---------------------------------|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | RELEASE OF SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Crescent Capital BDC, Inc. (as successor by merger with Alcentra Capital Corporation) | | 03/19/2021 | Corporation: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | Pharmalogic Holdings Corp. | | |
| Street Address: | One South Ocean Blvd. | | |
| Internal Address: | Suites 206 and 208 | | |
| City: | Boca Raton | | |
| State/Country: | FLORIDA | | |
| Postal Code: | 33432 | | |
| Entity Type: | Limited Liability Company: DELAWARE | | |
| PROPERTY NUMBERS Total: 3 | | | |
| Property Type | Number | Word Mark | |
| Registration Number: | 2825794 | PHARMA-LOGIC | |
| Registration Number: | 2718736 | PHARMA-LOGIC THE LOGICAL CHOICE | |
| Registration Number: | 2666078 | PHARMALOGIC | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Email: | stokesb@gtlaw.com | | |
| Correspondent Name: | Bethany A. Stokes | | |
| Address Line 1: | Greenberg Traurig, LLP | | |
| Address Line 2: | One International Place, Suite 2000 | | |
| Address Line 4: | Boston, MASSACHUSETTS 02110 | | |
| ATTORNEY DOCKET NUMBER: | 183305.010200 | | |
| NAME OF SUBMITTER: | Bethany A. Stokes | | |
| SIGNATURE: | /Bethany A. Stokes/ | | |
| DATE SIGNED: | 03/23/2021 | | |
| Total Attachments: 4 | | | |

CH \$90.00 2825794

source=PharmaLogic - Trademark Release (PharmaLogic)#page1.tif
source=PharmaLogic - Trademark Release (PharmaLogic)#page2.tif
source=PharmaLogic - Trademark Release (PharmaLogic)#page3.tif
source=PharmaLogic - Trademark Release (PharmaLogic)#page4.tif

**TERMINATION AND RELEASE OF
SECURITY INTEREST IN TRADEMARKS**

This TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Release"), dated as of March 19, 2021, is made by Crescent Capital BDC, Inc. (as successor by merger with Alcentra Capital Corporation), as Administrative Agent (the "Agent"), in favor of PHARMALOGIC HOLDINGS CORP. (the "Grantor").

WITNESSETH:

WHEREAS, pursuant to the Second Lien Security and Pledge Agreement, dated as of June 11, 2018, among the Agent and Grantor and the other parties thereto (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Security Agreement"), Grantor has granted a continuing security interest in and continuing lien upon certain collateral to the Agent;

WHEREAS, pursuant to the Security Agreement, the Grantor executed and delivered a Short Form Intellectual Property Security Interest in Trademarks Agreement, between the Agent and Grantor, dated June 11, 2018 (the "Trademark Security Agreement"), for recordal with the United States Patent and Trademark Office.

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on June 11, 2018, at Reel 6351 and Frame 0090;

WHEREAS, the Agent now desires to terminate and release the entirety of its security interest in the Collateral;

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and upon the terms set forth in this Release, the Agent hereby states as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the Trademark Security Agreement, as applicable.

2. Release of Security Interest. The Agent, without representation or warranty of any kind, hereby terminates, releases, cancels and discharges all of its security interest in and to the Collateral, including the trademark registrations and applications set forth in Schedule A attached hereto, arising under the Security Agreement and the Trademark Security Agreement. If and to the extent that the Agent has acquired any right, title or interest in and to the Collateral under the Trademark Security Agreement, the Agent, without representation or warranty of any kind, hereby re-transfers, re-conveys and re-assigns such right, title or interest to the Grantor.


3. Termination. The Agent, without representation or warranty of any kind, terminates and cancels the Trademark Security Agreement.

4. Further Assurances. The Agent hereby agrees to duly execute, acknowledge, procure and deliver any further documents and to do such other acts as may be reasonably necessary to effect the release of the security interest contemplated hereby, in the case of the foregoing, as may be reasonable requested by the Grantor, and at the sole cost and expense of the Grantor.

5. Governing Law. The terms of the Credit Agreement with respect to governing law, submission to jurisdiction, venue and waiver of jury trial (and where applicable, judicial reference) are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.


IN WITNESS WHEREOF, the undersigned has executed this Release by its duly authorized officer as of the date first above written.

Crescent Capital BDC, Inc. (as successor by merger
with Alcentra Capital Corporation),
as Administrative Agent

By: 
Name: Henry Chung
Title: Senior Vice President

Schedule A

Trademark Registrations and Applications

| Trademark | Country | Class | Reg. No. | Reg. Date |
|---|---------|--------------|-----------|------------|
| PHARMA-LOGIC | U.S. | 5 | 2,825,794 | 03/23/2004 |
|  | U.S. | 1, 5, 35, 40 | 2,718,736 | 05/27/2003 |
| PHARMA LOGIC | U.S. | 1, 5, 35, 40 | 2,666,078 | 12/24/2002 |

ACTIVE 55512691v2

RECORDED: 03/23/2021

TRADEMARK
REEL: 007229 FRAME: 0461